LLY

Viking Therapeutics’ inventory greater than doubles as traders cheer low cost entry to weight-loss-drug craze

A rising variety of shares are becoming a member of the market rally — at the same time as Big Tech nonetheless will get a lot of the consideration

Why revenue hunters ought to go for dividend compounders over high-yielding shares

What to consider ‘Peak 65’

Disney board nominates slate of dozen administrators that excludes activist buyers

Fusion Pharma climbs as radiopharmaceutical firm flagged as potential merger goal

Five obesity-drug tendencies to observe in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

Nvidia, Disney and Tesla are amongst 2023’s buzziest shares. Can they proceed to sizzle in 2024?

LifeMD’s inventory soars 13% as firm and Medifast to create weight-management program that features GLP-1 medication

Roche strikes $3.1 billion deal to purchase obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk’s Ozempic